PP
TBPH icon

PDT Partners’s Theravance Biopharma TBPH Stock Holding History

PDT Partners’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$487K Sell
28,629
-5,167
-15% -$85.5K 0.03% 402
2026
Q1 		$549K Sell
33,796
-58,761
-63% -$1.04M 0.03% 412
2025
Q4 		$1.73M Sell
92,557
-17,152
-16% -$285K 0.11% 270
2025
Q3 		$1.6M Sell
109,709
-10,618
-9% -$134K 0.1% 294
2025
Q2 		$1.33M Buy
120,327
+31,750
+36% +$309K 0.08% 370
2025
Q1 		$791K Buy
88,577
+50,901
+135% +$474K 0.06% 435
2024
Q4 		$355K Sell
37,676
-49,501
-57% -$450K 0.03% 540
2024
Q3 		$703K Buy
87,177
+20,738
+31% +$180K 0.06% 442
2024
Q2 		$563K Hold
66,439
– – 0.05% 441
2024
Q1 		$596K Buy
66,439
+34,016
+105% +$315K 0.06% 421
2023
Q4 		$364K Sell
32,423
-49,035
-60% -$494K 0.04% 444
2023
Q3 		$703K Sell
81,458
-700
-0.9% -$6.76K 0.09% 360
2023
Q2 		$850K Sell
82,158
-203
-0.2% -$2.24K 0.12% 284
2023
Q1 		$894K Buy
82,361
+39
+0% +$412 0.12% 290
2022
Q4 		$924K Buy
82,322
+664
+0.8% +$6.98K 0.15% 246
2022
Q3 		$828K Sell
81,658
-74,473
-48% -$698K 0.13% 276
2022
Q2 		$1.42M Sell
156,131
-36,570
-19% -$337K 0.12% 264
2022
Q1 		$1.84M Buy
192,701
+81,322
+73% +$797K 0.16% 195
2021
Q4 		$1.23M Buy
+111,379
New +$971K 0.09% 318
2021
Q1 		– Sell
-54,522
Closed -$969K – 881
2020
Q4 		$969K Sell
54,522
-11,539
-17% -$207K 0.07% 328
2020
Q3 		$977K Buy
66,061
+41,447
+168% +$776K 0.06% 308
2020
Q2 		$517K Buy
+24,614
New +$632K 0.04% 402
2015
Q4 		– Sell
-17,683
Closed -$194K – 905
2015
Q3 		$194K Sell
17,683
-25,244
-59% -$321K ﹤0.01% 1165
2015
Q2 		$559K Buy
42,927
+26,534
+162% +$412K 0.01% 939
2015
Q1 		$284K Buy
+16,393
New +$300K 0.01% 1174

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

PDT Partners's TBPH Position: Q2 2026 in Review

PDT Partners reduced its Theravance Biopharma (TBPH) stake by 15% in Q2 2026, selling an estimated $85.5K and leaving 28,629 shares worth $487K. The position accounts for 0.03% of the portfolio, ranked #402.

PDT Partners first reported a position in TBPH in Q1 2015 and has held it in 25 quarters since. The position peaked at $1.84M in Q1 2022. 181 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • PDT Partners held 28,629 shares of Theravance Biopharma worth $487K as of Q2 2026.
  • PDT Partners sold 5,167 Theravance Biopharma shares in Q2 2026, an estimated $85.5K.
  • Theravance Biopharma made up 0.03% of PDT Partners's portfolio in Q2 2026, its #402 holding.
  • PDT Partners first reported a position in Theravance Biopharma in Q1 2015 and has held it in 25 quarters since.
  • PDT Partners's Theravance Biopharma position peaked at $1.84M in Q1 2022.
  • 181 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on PDT Partners's 13F filing for Q2 2026, filed 14 Aug 2026.